Refrences
1. Organization, W.H. WHO Coronavirus Disease (COVID-19) Dashboard . 2021 February 4th, 2021; Available from: https://covid19.who.int/.
2. Shang, W., et al., The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. npj Vaccines, 2020. 5 (1): p. 1-3.
3. Ayotte, K., J. Gerberding, and J.S. Morrison, Ending the Cycle of Crisis and Complacency in US Global Health Security: A Report of the CSIS Commission on Strengthening America’s Health Security . 2020: Center for Strategic & International Studies.
4. WHO, Draft landscape of COVID-19 candidate vaccines. World Health Organisation, 2020.
5. Cohen, J.I. and P.D. Burbelo, Reinfection with SARS-CoV-2: Implications for Vaccines. Clinical Infectious Diseases, 2020.
6. Gudbjartsson, D.F., et al., Humoral immune response to SARS-CoV-2 in Iceland. New England Journal of Medicine, 2020.383 (18): p. 1724-1734.
7. Crawford, K.H., et al., Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. MedRxiv, 2020.
8. Dickson, M., R. Mathews, and G.G. Menon, ANALYSIS OF COVID-19 REINFECTION RATES AND ITS UNDERLYING CAUSES: A SYSTEMATIC REVIEW. 2020.
9. Krishna, E., et al., COVID-19 reinfection: Linked possibilities and future outlook. Journal of Family Medicine and Primary Care, 2020.9 (11): p. 5445.
10. Osman, A., M. Al Daajani, and A. Alsahafi, Re-positive coronavirus disease 2019 PCR test: could it be a reinfection? New Microbes New Infect . 2020.
11. Plotkin, S.A., Correlates of protection induced by vaccination. Clinical and vaccine immunology, 2010. 17 (7): p. 1055-1065.
12. Seow, J., et al., Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. MedRxiv, 2020.
13. Long, Q.-X., et al., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature medicine, 2020.26 (8): p. 1200-1204.
14. Koyama, T., D. Platt, and L. Parida, Variant analysis of SARS-CoV-2 genomes. Bulletin of the World Health Organization, 2020.98 (7): p. 495.
15. Tillett, R.L., et al., Genomic evidence for reinfection with SARS-CoV-2: a case study. The Lancet Infectious Diseases, 2021.21 (1): p. 52-58.
16. Prado-Vivar, B., et al., COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America. First Confirmed Event in South America.(September 3, 2020), 2020.
17. Van Elslande, J., et al., Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis, 2020.10 .
18. Scaria, V., Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. 2020.
19. Mo, H., et al., Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance.Respirology, 2006. 11 (1): p. 49-53.
20. Payne, D.C., et al., Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerging infectious diseases, 2016. 22 (10): p. 1824.
21. Yahav, D., et al., Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect, 2020.
22. Arevalo-Rodriguez, I., et al., False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PloS one, 2020. 15 (12): p. e0242958.
23. Luo, A., Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital discharge: A case report. Journal of Traditional Chinese Medical Sciences, 2020. 7 (4): p. 413-417.
24. Organization, W.H., Criteria for releasing COVID-19 patients from isolation: scientific brief, 17 June 2020 . 2020, World Health Organization.
25. Tao, W., et al., Re-detectable positive SARS-CoV-2 RNA tests in patients who recovered from COVID-19 with intestinal infection.Protein & cell, 2020: p. 1-6.
26. Kang, H., et al., Retest positive for SARS‐CoV‐2 RNA of “recovered” patients with COVID‐19: Persistence, sampling issues, or re‐infection? Journal of medical virology, 2020. 92 (11): p. 2263-2265.
27. Chen, Y., et al., Re-evaluation of retested nucleic acid-positive cases in recovered COVID-19 patients: Report from a designated transfer hospital in Chongqing, China. Journal of infection and public health, 2020. 13 (7): p. 932-934.
28. Control, C.f.D. and Prevention, Duration of isolation and precautions for adults with COVID-19. 2020 . 2020.
29. Lu, J., et al., Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. EBioMedicine, 2020. 59 : p. 102960.
30. Bonifácio, L.P., et al., Are SARS-CoV-2 reinfection and Covid-19 recurrence possible? a case report from Brazil. Revista da Sociedade Brasileira de Medicina Tropical, 2020. 53 .
31. Ye, G., et al., Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. Journal of Infection, 2020. 80 (5): p. e14-e17.
32. Ravioli, S., H. Ochsner, and G. Lindner, Reactivation of COVID-19 pneumonia: a report of two cases. The Journal of infection, 2020.
33. Kang, Y.J. and H. Joo, South Korea’s COVID-19 infection status: From the perspective of reconfirmation after complete recovery.Journal of Pure and Applied Microbiology, 2020. 14 .
34. Loconsole, D., et al., Recurrence of COVID-19 after recovery: a case report from Italy. Infection, 2020: p. 1-3.
35. Anwar, H. and Q.U. Khan, Pathology and Therapeutics of COVID-19: A Review. International Journal of Medical Students, 2020.8 (2): p. 113-120.
36. Xie, C., et al., False negative rate of COVID-19 is eliminated by using nasal swab test. Travel medicine and infectious disease, 2020.
37. Zhang, D., et al., COVID‐19 infection induces readily detectable morphologic and inflammation‐related phenotypic changes in peripheral blood monocytes. Journal of leukocyte biology, 2020.
38. Elberry, M.H. and H. Ahmed, Occult SARS-CoV-2 infection; a possible hypothesis for viral relapse. Medical hypotheses, 2020.144 : p. 109980.
39. Mondal, R., et al., Recurrence of COVID-19: Treading the Fine Line Between Relapse and Re-infection. International Journal of Medical Students, 2020. 8 (3): p. 311-313.
40. To, K.K.-W., et al., COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious diseases, 2020.
41. Chen, X., et al., Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal transduction and targeted therapy, 2020. 5 (1): p. 1-6.
42. Larson, D., et al., A Case of Early Re-infection with SARS-CoV-2. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2020.
43. Iwasaki, A., What reinfections mean for COVID-19. The Lancet Infectious Diseases, 2021. 21 (1): p. 3-5.
44. Gousseff, M., et al., Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? Journal of Infection, 2020. 81 (5): p. 816-846.
45. Chen, Z. and E.J. Wherry, T cell responses in patients with COVID-19. Nature Reviews Immunology, 2020. 20 (9): p. 529-536.
46. Channappanavar, R., et al., Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. Journal of virology, 2014.88 (19): p. 11034-11044.
47. Zhao, J., et al., Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clinical infectious diseases, 2020. 71 (16): p. 2027-2034.
48. Liu, A., et al., Antibody responses against SARS‐CoV‐2 in COVID‐19 patients. Journal of medical virology, 2021. 93 (1): p. 144-148.
49. Iyer, A.S., et al., Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science immunology, 2020. 5 (52).
50. Baumgarth, N., et al., Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns. The Journal of Immunology, 2020.205 (9): p. 2342-2350.
51. Amanna, I.J., N.E. Carlson, and M.K. Slifka, Duration of humoral immunity to common viral and vaccine antigens. New England Journal of Medicine, 2007. 357 (19): p. 1903-1915.
52. Zhang, J., et al., COVID-19 reinfection in the presence of neutralizing antibodies. National Science Review, 2021.